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Abstract: Valproic acid (VPA) is considered to be a drug of ﬁ  rst choice for the therapy of 
generalized and focal epilepsies, including special epileptic syndromes. The drug is usually 
well tolerated, rare serious complications may occur in some patients, including hemorrhagic 
pancreatitis, coagulapathies, bone marrow suppression, VPA-induced hepatotoxicity and 
encephalopathy. We report a case of VPA-associated encephalopathy without hyperammone-
mia in a 3-year-old girl with Pallister-Killian-Syndrom, combined with a mild hepatopathy and 
thrombopathy. After withdrawal of VPA, the clinical symptoms and the electroencephalogra-
phy-alterations vanished rapidly.
Keywords: pallister-killian, valproate, encephalopathy, EEG, ammonia
Case report
Pallister-Killian syndrome is an extremely rare genetic disorder that occurs due to 
tetrasomy of the twelfth chromosome (tissue-limited isochromosome 12p). Symptoms 
include varying degrees of mental retardation, epilepsy, or hypotonia. Patients also 
exhibit a distinctive facial structure, characterized by high foreheads, sparse hair on the 
temple, a wide space between the eyes, a fold of skin over the inner corner of the eyes, 
and a ﬂ  at nose. Patients may also exhibit congenital heart defects, gastroesophageal 
reﬂ  ux, cataracts, and congenital diaphragmatic hernias (CDH).
Because of a prenatal diagnosed sinistral CDH, the ﬁ  rst-born of healthy, noncon-
sanguine parents was a patient in our intensive care united. The patient was born in the 
36th week of gestation with a birth weight of 2.74 kg. The hernia was closed ﬁ  ve days 
after birth without any severe complications. However, after a period of 5 months, the 
child showed typical symptoms of a Pallister-Killian syndrome with focal seizures, 
hypotonia, and the characteristical facial features. The diagnosis was conﬁ  rmed by 
detection in samples of skin ﬁ  broblasts.
Anticonvulsant therapy was initiated with oxcarbazepine (OCBZ) up to a level of 
30 mg/kg/BW. The seizures stopped for the next 10 months, but the electroencephalog-
raphy (EEG) still showed multifocal sharp-waves. At the age of 13 months, the seizures 
returned with focale myoclonias and atypical absences. We decided to add VPA to 
OCBZ and achieved complete seizure control with a VPA-level of 25 mg/kg/BW. The 
child didn’t show any incompatibilities or side effects associated to the antiepileptic 
therapy. Before the VPA-therapy was started, extended laboratory tests (including 
metabolic disorder screenings) were done. This included disorders in amino acid, 
carbohydrate, beta-oxidation, urea-cycle, and carnitin metabolism.
At the age of 38 months the girl was presented at our emergency ward with 
increased seizure frequency, augmented fatigue, and vomiting. On examination the 
girl appeared moderately ill, but the mother was worried about a signiﬁ  cant reduc-
tion in alertness and attention. The laboratory investigations showed slight changes Therapeutics and Clinical Risk Management 2008:4(3) 646
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in transaminases and decreased platelets. Additionally we 
found generalized slowing (theta-delta-activity) in the EEG, 
in contrast with former EEG ﬁ  ndings. The serum-VPA-level 
was 90 mg/l, the serum ammonia showed normal levels 
(Table 1).
We immediately stopped the VPA medication but contin-
ued the antiepileptic therapy with OCBZ. In the course of the 
next ten days the medical condition as well as the laboratory 
ﬁ  ndings improved. The EEG-pathologies normalized within 
4 days after withdrawal of VPA.
The antiepileptic medication was continued with OCBZ 
and topiramate (TPM) in unmodiﬁ  ed dosages. Although a 
few publications showed an increased risk of encephalopathy 
when VPA was combined with TPM (Longin et al 2002; 
Cheung et al 2005), there is only one paper that shows an 
increased risk of encephalopathy with TPM monotherapy in 
adults. Long-term inhibition of cerebral glutamine synthetase 
and TPM as an inhibitor of carbonic anhydrase, which leads 
to hyperammonemia because it restricts the path of the urea 
cycle were appointed as possible mechanisms (Fraser et al 
1999; Latour et al 2004).
The focal slowing of the EEG vanished, the seizure 
frequency remained acceptable, and the girl’s vigilance 
normalized.
Conclusion
In most cases, VPA is a well tolerated antiepileptic drug 
with high effectiveness in seizure control. Most of the side 
effects are mild and transient, but there are also rare, but 
severe side effects, especially hepatotoxicity (Koenig et al 
2006), encephalopathy (Gerstner et al 2006a), coagulation 
disorders (Gerstner et al 2006b), pancreatitis (Gerstner et al 
2007), and bone marrow suppression (Acharya and Bussel 
2000; Kohli and Golsti 2006).
In our case of a two-year-old girl with Pallister-Killian 
syndrome, we found a combination of encephalopathy, 
thrombopenia, and slight hepatopathy associated with a 
VPA-therapy.
Interestingly, the girl received the VPA-therapy for 
about 2 years at the same dosage without any signs of 
encephalopathy. According to previous publications, VPA-
associated side effects vanish rapidly under withdrawal of 
VPA (Gerstner et al 2006a). A chromosomal alteration 
due to the underlying syndrome in this patient wasn’t ever 
described as a predisposition for a VPA (drug) associated 
encephalopathy.
Especially in mentally retarded patients, the physi-
cians should show speciﬁ  c advertence to VPA-associated 
problems. An overhaul of parameters like blood count, 
coagulation parameters, transaminases, ammonia, and 
pancreatic enzymes is necessary, the EEG could provide 
further indices of a VPA-associated encephalopathy. As 
shown here, VPA-associated encephalopathy could be 
presented without increased ammonia and with a lack of 
pronounced symptoms. Additionally, every new changes in 
transaminases, lipase, coagulation parameters or blood count 
is suspicious for a VPA-associated effect. The encephalopa-
thy could appear with hyperammonemia, but also without 
hyperammonemia, possibly as a direct inﬂ  uence of VPA 
on neurotransmitters (Kwan and Brodie 2001). In this case, 
the encephalopathy is not related to the VPA plasma level. 
Another possible mechanism is direct neuronal toxicity 
induced by increased intracellular concentrations of gluta-
mate and ammonium in astrocytes (Ricard et al 2005), which 
may lead to potential neuronal injury and perhaps cerebral 
edema (Verrotti et al 2002).
In consideration of this approach, the side effects van-
ish and the patients’ outcome is proper. At this time, we 
do not understand why most patients never have any side 
effects related to VPA and why other patients show such 
a variety of side effects related to different mechanisms. 
Our patient emphasizes nevertheless that VPA-associated 
encephalopathy has to be looked for in any individual patient 
and that they may be totally reversible after withdrawal of 
VPA. Sometimes, the EEG is the only diagnostic criteria of 
ﬁ  nding the diagnosis.
From our case we can learn, that VPA-associated side 
effects can occur at any time of the VPA-therapy. Especially 
in psychomotoric retarded patients, the physicians should 
show speciﬁ  c advertence to VPA-associated problems. An 
overhaul of parameters like blood count, coagulation param-
eters, transaminases, ammonia and pancreatic enzymes is 
necessary, the EEG could provide further indices of a VPA-
associated encephalopathy.
Table 1 Overview of laboratory ﬁ  ndings
 Laboratory  ﬁ  ndings  Laboratory ﬁ  ndings
  while presented at  10 day after
  the pediatric ward
Valproic acid-level  90 mg/dl  –
Ammonia 16  µmol/l –
ALAT/ASAT  73 U/l/ 63U/l  42U/l/ 45U/l
Lipase 133U/l  159U/l
Platelets 83000/µl 220000/µl
White blood cells  6500/µl 8900/µl
Red blood cells  hb 12.2g/dl, erythr.   hb 12,1g/dl, erythr.
 3.45  Mill./µl 3,88  Mill./µlTherapeutics and Clinical Risk Management 2008:4(3) 647
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In case of such side effects, an immediate withdrawal is 
required and a supportive therapy with intravenous carni-
tine could be necessary, when signs of hepatopathy occur 
additionally.
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